AllSci News
Tecelra converts to full US FDA approval, extends use to patients aged 12 and older
Louisville, Kentucky-based US WorldMeds has received full US FDA approval for Tecelra (afamitresgene autoleucel), the TCR-T cell therapy originally developed by Adaptimmune…
Cancer Cell publication provides biological rationale for sac-TMT's Phase III push into first-line EGFR-mutant NSCLC
Translational research published in Cancer Cell this week offers a mechanistic rationale for one of the most strategically significant combination studies...
Exelixis reports split Phase III outcome for zanzalintinib ahead of FDA review
Exelixis, Inc. (Nasdaq: EXEL) reported that the final analysis of its second dual primary endpoint in the Phase III STELLAR-303 trial did not reach...
Bionyra launches with USD 165m to challenge TL1A incumbents in inflammatory disease
France-based Bionyra Pharma, a clinical-stage biopharmaceutical company developing mono and multispecific antibodies for immune-mediated inflammatory...
Nura Bio's USD 73.8m Series B validates SARM1 inhibition strategy in ALS
South San Francisco-based Nura Bio, Inc., a clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies, has completed a...
MoonLake reports best-in-class one-year HS data for sonelokimab
Switzerland-based MoonLake Immunotherapeutics (Nasdaq: MLTX) reported Week 52 data from its Phase III VELA-1 and VELA-2 trials showing that 67.2% of adults...
101 Therapeutics bypasses peer review to seek emergency evaluation of Ebola therapy candidate
Israel and New Jersey-based 101 Therapeutics Ltd. has released Phase II/III clinical data for 101-PGC-005, a macrophage-targeted dexamethasone prodrug,...
Lilly bets USD 800m on BioArctic’s blood-brain barrier platform for neurodegeneration
Sweden-based BioArctic AB (Nasdaq Stockholm: BIOA B) and Eli Lilly and Company have announced a research and collaboration agreement to combine BioArctic’s…
Regenxbio's Navsunli clears FDA path toward first gene therapy for Hunter syndrome
Rockville, Maryland-based REGENXBIO Inc. (Nasdaq: RGNX) has announced alignment with the US FDA on a path forward for resubmission of the Biologics License...
Nuvectis licenses Haisco's late-stage Factor B inhibitor and BRAF program in USD 1.4b deal
Fort Lee, New Jersey-based Nuvectis Pharma, Inc. (Nasdaq: NVCT) has signed an exclusive ex-China license agreement with China-based Haisco Pharmaceutical...
Regeneron seeking approval for cemdisiran as first siRNA therapy for generalized myasthenia gravis
Regulatory applications for cemdisiran, a small interfering RNA (siRNA) therapeutic targeting complement factor C5, have been accepted for review by both...
Harbour BioMed wins US verdict validating antibody discovery platform patent against Amgen
China-based Harbour BioMed (HKEX: 02142) has secured a unanimous jury verdict in the US District Court for the District of Delaware against…
AbbVie adds long-acting IL-13 assets in USD 10.9 billion Apogee acquisition
AbbVie (NYSE: ABBV) has agreed to acquire Apogee Therapeutics (Nasdaq: APGE) in an all-cash transaction valued at approximately USD 10.9 billion, adding a...
Greenstone-Intel collaboration highlights growing role of AI infrastructure in human-cell drug discovery
Palo Alto-based Greenstone Biosciences, Inc. and Intel Corporation have announced a strategic collaboration that brings one of the largest human induced pluripotent…
Insilico's USD 2.5 billion SK Biopharmaceuticals deal validates AI-first drug discovery at scale
Insilico Medicine (HKEX: 3696) has struck a neuroimmune drug discovery collaboration with South Korea-based SK Biopharmaceuticals (KRX: 326030.KS) worth up...
The AllSci Brief
Systematic R&D and deal news. Daily.